Effectiveness of a 23-valent pneumococcal polysaccharide vaccine for the prevention of pneumococcal pneumonia in the elderly with chronic respiratory diseases: a case-control study of a single center

被引：4

作者：

Masuda, Toshihiro ^{[1
]}

Nakatani, Eiji ^{[2
,3
]}

Shirai, Toshihiro ^{[1
]}

Akamatsu, Taisuke ^{[1
]}

Tamura, Kanami ^{[1
]}

Takahashi, Shingo ^{[1
]}

Tanaka, Yuko ^{[1
]}

Watanabe, Hirofumi ^{[1
]}

Endo, Yoshinari ^{[1
]}

Suzuki, Takahito ^{[1
]}

Saigusa, Mika ^{[1
]}

Yamamoto, Akito ^{[1
]}

Morita, Satoru ^{[1
]}

Sato, Yoko ^{[2
]}

Asada, Kazuhiro ^{[1
]}

机构：

[1] Shizuoka Prefectural Gen Hosp, Dept Resp Med, Shizuoka, Japan

[2] Shizuoka Prefectural Gen Hosp, Res Support Ctr, Div Clin Biostat, 4-27-1 Kita Ando, Shizuoka 4208527, Japan

[3] Shizuoka Grad Univ Publ Hlth, Grad Sch Publ Hlth, Aoi Ku, 4-27-2 Kitaando, Shizuoka 4200881, Japan

来源：

BMC PULMONARY MEDICINE | 2021年 / 21卷 / 01期

关键词：

Chronic respiratory disease; Elderly; Pneumococcal polysaccharide vaccine; Pneumococcus; Pneumonia; Vaccine;

D O I：

10.1186/s12890-021-01491-w

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Background The effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in preventing pneumococcal pneumonia has been controversial. Methods To evaluate the effectiveness of the PPSV23 in elderly outpatients with chronic respiratory diseases, we carried out a case-control study, including 4128 outpatients aged >= 65 years, in the respiratory department. Results There were 320 vaccinated patients, of which 164 were diagnosed with pneumococcal pneumonia. The adjusted odds ratio was 0.39 (95% confidence interval (CI), 0.17 to 0.89). In the subsets consisting of age groups >= 70 and >= 75 years, the adjusted odds ratio (95% CI) was respectively 0.16 (0.04 to 0.67) and 0.15 (0.02 to 1.12). Conclusion This real-world study suggests that PPSV23 can be useful in preventing pneumococcal pneumonia in the elderly with chronic respiratory diseases.

引用

页数：6

共 50 条

[41] The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales
Melegaro A.
Edmunds W.J.
European Journal of Epidemiology, 2004, 19 (4) : 365 - 375
[42] Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease among 948,263 individuals ≥ 65 years of age: a Danish cohort study
Nielsen, Katrine Finderup
Nielsen, Lise Birk
Lomholt, Frederikke Kristensen
Norgaard, Sarah Kristine
Slotved, Hans-Christian
Dalby, Tine
Fuursted, Kurt
Jorgensen, Charlotte Svaerke
Valentiner-Branth, Palle
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2022, 41 (12) : 1473 - 1477
[43] Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease among 948,263 individuals ≥ 65 years of age: a Danish cohort study
Katrine Finderup Nielsen
Lise Birk Nielsen
Frederikke Kristensen Lomholt
Sarah Kristine Nørgaard
Hans-Christian Slotved
Tine Dalby
Kurt Fuursted
Charlotte Sværke Jørgensen
Palle Valentiner-Branth
European Journal of Clinical Microbiology & Infectious Diseases, 2022, 41 : 1473 - 1477
[44] Effectiveness of the 10-valent pneumococcal conjugate vaccine on pediatric pneumonia confirmed by ultrasound: a matched case-control study
Checkley, William
Hossen, Shakir
McCollum, Eric D.
Pervaiz, Farhan
Miele, Catherine H.
Chavez, Miguel A.
Moulton, Lawrence H.
Simmons, Nicole
Roy, Arunangshu D.
Chowdhury, Nabidul H.
Ahmed, Salahuddin
Begum, Nazma
Quaiyum, Abdul
Santosham, Mathuram
Baqui, Abdullah H.
RESPIRATORY RESEARCH, 2022, 23 (01)
[45] Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and previously immunized adult patients with severe chronic kidney disease
Ulanova, Marina
Huska, Brenda
Desbiens, Angele
Gaultier, Gabrielle N.
Domonkos, Victoria
McCready, William G.
VACCINE, 2021, 39 (04) : 699 - 710
[46] Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark
Nielsen, Katrine Finderup
Nielsen, Lise Birk
Dalby, Tine
Lomholt, Frederikke Kristensen
Slotved, Hans-Christian
Fuursted, Kurt
Harboe, Zitta Barrella
Jorgensen, Charlotte Svaerke
Valentiner-Branth, Palle
EMERGING INFECTIOUS DISEASES, 2024, 30 (06) : 1164 - 1172
[47] Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England andWales
Djennad, Abdelmajid
Ramsay, Mary E.
Pebody, Richard
Fry, Norman K.
Sheppard, Carmen
Ladhani, Shamez N.
Andrews, Nick J.
ECLINICALMEDICINE, 2018, 6 : 42 - 50
[48] Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine Against Community-Acquired Pneumonia in the General Population Aged ≥60 Years: 3 Years of Follow-up in the CAPAMIS Study
Ochoa-Gondar, Olga
Vila-Corcoles, Angel
Rodriguez-Blanco, Teresa
Gomez-Bertomeu, Frederic
Figuerola-Massana, Enric
Raga-Luria, Xavier
Hospital-Guardiola, Imma
CLINICAL INFECTIOUS DISEASES, 2014, 58 (07) : 909 - 917
[49] The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: A comparison of meta-analyses
Melegaro A.
Edmunds W.J.
European Journal of Epidemiology, 2004, 19 (4) : 353 - 363
[50] The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: A comparison of meta-analyses
Melegaro, A
Edmunds, WJ
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2004, 19 (04) : 353 - 363

← 1 2 3 4 5 →